Lilly Secures Lead as Zepbound Surges While Wegovy Growth Stalls
Zepbound sales up 46% for Eli Lilly in Q2
Oral Wegovy secures early lead in U.S. market for Novo
Lilly's Foundayao gains ground after insurance coverage expansion
Eli Lilly's dominance in the global anti-obesity drug market is solidifying. While Eli Lilly's injectable Zepbound continued its high growth, Novo Nordisk's injectable Wegovy sales remained largely stagnant. Although Novo Nordisk is leading in the oral obesity drug sector, Eli Lilly is quickly closing the gap with expanded insurance coverage.
According to the pharmaceutical and biotech industry on August 6, Eli Lilly announced on August 5 (local time) that its second-quarter revenue reached $22.974 billion, a 48% increase from the same period last year (approximately KRW 32.7035 trillion). Zepbound, its obesity treatment, recorded sales of $4.9 billion (approximately KRW 6.9752 trillion), up 46%. The diabetes treatment Mounjaro, which uses the same tirzepatide ingredient, posted sales of $9.9 billion (approximately KRW 14.0927 trillion), up 91%. Together, these two products accounted for 64% of the company's overall revenue.
Novo Nordisk’s flagship product, the injectable Wegovy, recorded sales of DKK 19.484 billion (approximately KRW 4.2861 trillion), with the increase from the previous year limited to just 1%. Although prescription volumes rose in the critical U.S. market, unit price declines led to a 22% decrease in Wegovy's injectable sales. The oral version of Wegovy, launched this year, generated sales of DKK 3.218 billion (approximately KRW 707.9 billion).
Injectables: Lilly Leads, Orals: Novo Dominates
Leadership in the U.S. injectable anti-obesity drug market has already shifted to Eli Lilly. Over recent months, weekly prescriptions of Zepbound have more than doubled those of injectable Wegovy. In the broader U.S. incretin market, which includes diabetes therapies, Eli Lilly holds a 60.9% share, outpacing Novo Nordisk’s 38.8%. The oral market, however, tells a different story. Novo Nordisk has stated that oral Wegovy now holds about 90% of the U.S. oral obesity drug market. Still, sales of the oral formulation are just one-sixth the size of the injectable, not sufficient to offset decreased injectable sales in the U.S.
Eli Lilly is making a full-scale entry into the oral market as well. In its debut quarter, the oral drug POUNDAYO reported sales of $98 million (approximately KRW 139.5 billion), but prescriptions have grown rapidly since it was added to the formularies of all three major U.S. pharmacy benefit managers (PBMs) in June. Prescriptions in the final week of last month doubled compared to a month earlier. During the same period, the number of prescribing physicians surged from 8,000 to 36,000.
Following Zepbound, the next in line is the triple agonist retatrutide. Acting on GLP-1 (glucagon-like peptide-1), GIP (gastric inhibitory polypeptide), and glucagon receptors, retatrutide demonstrated an average weight loss of 28.3% over 80 weeks in a phase 3 clinical trial with a 12 mg dose group. Eli Lilly plans to file for U.S. approval in 2027.
Novo Nordisk is focusing more on broadening the use of Wegovy than on introducing entirely new brands. The company is continuing to expand the number of countries offering both oral Wegovy and the high-dose Wegovy 7.2 mg. Its key strength lies in leveraging accumulated safety and cardiometabolic clinical data, applying it to multiple formulations and indications within the same brand.
It will take more time for next-generation candidates to fully prove their competitiveness against Eli Lilly’s product lineup. Cagrisema demonstrated over 20% weight loss in trials on obese patients, but failed to show non-inferiority to tirzepatide in direct comparisons. Jenagamtide, which showed up to 24.3% weight loss in early trials, is currently undergoing a phase 3 trial.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
While the two market leaders are filling the space with injectables, orals, and high-dose products, challengers are seeking openings by targeting longer dosing intervals and improved tolerability. Amgen is developing maritide, designed for monthly or even longer dosing intervals; Pfizer is targeting monthly maintenance therapy with veverbenatide; and Roche is advancing CT-388, which demonstrated up to 22.5% weight loss in phase 2 clinical studies. In Korea, Hanmi Pharmaceutical is set to launch a domestically optimized epaglenatide-based obesity treatment within this year. Reporter: Lee Seongmin
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.